muciniphila were shown to contain proteins covering a wide range of molecular weights, from 11 to 245 kDa [43]
A good plan should answer what you are trying to improve, how progress will be measured, when early changes may appear, when the plan should be reassessed, what side effects should be watched for, what happens if it is not working, and how long the plan makes sense for your goal
The companies that are correctly positioned in this environment are those with robust pipeline depth, manufacturing efficiency advantages, and therapeutic areas where generic competition dynamics are unfavorable to Cost Plus-style pricing primarily biologics, where the regulatory and manufacturing complexity of biosimilar development creates slower and less complete price erosion than small-molecule generics experience
As noted by Mahiques-Santos, the higher incidence of side effects associated with MT-II is due to its being less receptor-specific than MT-I [1]